In Belize, a months-long public debate over prescription regulation for contraceptives is set to enter a 12-month phase-in period that has softened tensions, but the Pharmacy Association of Belize is holding firm to its core message: patient well-being remains the non-negotiable top priority.
As public discourse around contraceptive access has intensified in recent weeks, the association says the narrative around its position has been widely misconstrued. Far from pushing for restrictions on reproductive rights, organization representatives emphasize their work is rooted in a fundamental professional responsibility to protect public health, particularly as questions mount over unreported long-term impacts of hormonal contraceptive use.
Beverly Coleman, public relations officer for the Pharmacy Association of Belize, laid out the group’s stance in comments to local media, clarifying that the push for stronger prescription oversight is not an attempt to limit personal autonomy. “Personally, I am against controlling women’s reproductive rights — a woman’s body is hers to make her own choices,” Coleman explained. “Where we have failed in the past is in properly educating the public about what we actually stand for, and now it’s our job to make that clear to all people, especially women accessing contraceptives.”
Coleman went on to outline the core concern driving the association’s advocacy: the lack of localized research on how the synthetic hormones in contraceptives affect Belizean communities. Hormonal contraceptives introduce foreign chemical compounds to the human body, she noted, and there is little to no local data tracking what long-term impacts these compounds may have.
Over recent years, Coleman pointed out, Belize has seen a sharp, unexplained rise in chronic health conditions among younger populations, including hypertension and stroke. While the association stops short of drawing a definitive causal link to contraceptive use, the absence of research into potential connections leaves critical gaps in public health understanding that need to be addressed. “We don’t have the hard data to confirm any connection, only observations of worrying trends,” Coleman said. “That’s why we’re calling for greater transparency and monitoring — it’s not about restricting access, it’s about looking out for the long-term health of our patients.”